119 related articles for article (PubMed ID: 25487217)
1. Pretherapeutic dosimetry before 131I therapy of benign thyroid disease. A clinical practice assessment of dosimetric parameters.
Krohn T; Behrendt FF; Heinzel A; Müller B; Mottaghy FM; Verburg FA
Nuklearmedizin; 2015; 54(3):131-6. PubMed ID: 25487217
[TBL] [Abstract][Full Text] [Related]
2. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
3. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
Canzi C; Zito F; Voltini F; Reschini E; Gerundini P
Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
[TBL] [Abstract][Full Text] [Related]
4. Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not.
Krohn T; Hänscheid H; Müller B; Behrendt FF; Heinzel A; Mottaghy FM; Verburg FA
J Clin Endocrinol Metab; 2014 Nov; 99(11):4109-15. PubMed ID: 25033065
[TBL] [Abstract][Full Text] [Related]
5. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry prior to I-131-therapy of benign thyroid disease.
Hänscheid H; Lassmann M; Reiners C
Z Med Phys; 2011 Dec; 21(4):250-7. PubMed ID: 21531122
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of two simple methods for estimation of thyroidal 131I kinetics for dosimetry-based treatment of Graves' disease.
Traino AC; Xhafa B
Med Phys; 2009 Apr; 36(4):1212-8. PubMed ID: 19472628
[TBL] [Abstract][Full Text] [Related]
8. A thermoluminescent method for the evaluation of the
Meftah S; Kraiem T
Radiat Environ Biophys; 2021 May; 60(2):289-298. PubMed ID: 33797646
[TBL] [Abstract][Full Text] [Related]
9. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
[TBL] [Abstract][Full Text] [Related]
10. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
12. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass.
Orsini F; Traino AC; Grosso M; Guidoccio F; Boni G; Volterrani D; Mariani G
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401
[TBL] [Abstract][Full Text] [Related]
13. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
Traino AC; Di Martino F; Lazzeri M
Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific dosimetry for radioiodine therapy of the autonomous thyroid nodule.
Matheoud R; Canzi C; Reschini E; Zito F; Voltini F; Gerundini P
Med Phys; 2003 May; 30(5):791-8. PubMed ID: 12772986
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine therapy in patients with hyperthyroid disorder: standard versus dosimetric activity application.
Reinartz P; Zimny M; Schaefer W; Mueller B; Buell U; Sabri O
Nucl Med Commun; 2003 Dec; 24(12):1247-53. PubMed ID: 14627852
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine therapy of benign thyroid-disorders.
Hartmann T; Vach W; Frings L; Mix M; Meyer PT; Ruf J
Nuklearmedizin; 2017; 56(5):171-176. PubMed ID: 29533423
[TBL] [Abstract][Full Text] [Related]
17. Combination of ultrasound guided percutaneous microwave ablation and radioiodine therapy in benign thyroid diseases. A suitable method to reduce the 131I activity and hospitalization time?
Happel C; Korkusuz H; Koch DA; Grünwald F; Kranert WT
Nuklearmedizin; 2015; 54(3):118-24. PubMed ID: 25586901
[TBL] [Abstract][Full Text] [Related]
18. [The effective half-life of 131I during the treatment of autonomous thyroid disease with radioiodine].
Müller B; Bares R; Büll U
Nuklearmedizin; 1991 Jun; 30(3):71-6. PubMed ID: 1714566
[TBL] [Abstract][Full Text] [Related]
19. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
20. 131I dosimetry and thyroid stunning.
Gerard SK; Park HM
J Nucl Med; 2003 Dec; 44(12):2039-40; author reply 2040. PubMed ID: 14660731
[No Abstract] [Full Text] [Related]
[Next] [New Search]
